Authors
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to ClassificationNuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Latest:
No Efficacy Loss After Multiple Ustekinumab Biosimilar Switches in PsoriasisReal-world study shows plaque psoriasis stays controlled after 2 ustekinumab biosimilar switches, with stable labs and no serious adverse events.
Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the USProjected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab BiosimilarsPrerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Latest:
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRCFirst-line cetuximab beta injection has received NMPA marketing approval in RAS/BRAF wild-type metastatic colorectal cancer.
Latest:
FDA Approves First Biosimilars Interchangeable With Simponi/Simponi AriaImmgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth quarter of this year.
Latest:
Navigating Data Integrity for Generic Drug ApprovalsContinuous innovation is required in various technological aspects to effectively manage the challenges of vast clinical data.
Latest:
Biosimilar Adoption and Provider Performance in Medicare Value-Based Payment ModelsEvidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.
Latest:
Dr Stephen Hanauer Gives Insight Into Growing US Adalimumab MarketStephen Hanauer, MD, professor of medicine, Feinberg School of Medicine, Northwestern University, reflects on data concerning the potential for adalimumab biosimilars to gain significant market share.
Latest:
Expert Insights on Overcoming Patient Education Gaps, Biosimilar Financial HurdlesJosh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, explain that widespread biosimilar adoption requires addressing patient and provider education gaps through pharmacists and rectifying perverse financial incentives within health care contract structures.
Latest:
The Promise of Biosimilars Is Within Reach for Health SystemsA collaborative exercise with 16 health care organizations nets millions in savings.
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to ClassificationNuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and BeyondThe US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Latest:
A Promise Unfulfilled: The State of BiosimilarsFor biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.
Latest:
Integrating Biosimilars Into Retina and Neurology Practices Requires Careful PlanningSuccessfully integrating biosimilars into practices requires careful planning and execution, as they impact virtually all aspects of a practice.
Latest:
The Top 5 Biosimilar Articles for the Week of August 11Here are the top 5 biosimilar articles for the week of August 11, 2025.
Latest:
Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast CancerRyan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.
Latest:
Biosimilar Adoption and Provider Performance in Medicare Value-Based Payment ModelsEvidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance.
Latest:
FDA Approves Ranibizumab-hkdz as First Interchangeable, Available in Both Vials and Prefilled SyringesThe FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.
Latest:
Cimerli Offers a New, Interchangeable Biosimilar for Ocular ConditionsCimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.
Latest:
The Underlying Economics of Unbranded BiologicsUnbranded biologics primarily serve to uphold inflated list prices, typically prompted by loss of exclusivity, aiming to safeguard market share and counter biosimilar competition, although forthcoming legislative changes targeting high drug costs could lessen their significance moving forward.
Latest:
Column: India Struggles to Meet International Biologics StandardsAn internationally recognized authority on biosimilar development discusses varieties of copy biologics in India and the need to distinguish these from true biosimilars.
Latest:
FDA Approves Teva Biosimilar for Denosumab in OsteoporosisThe FDA approved Teva’s biosimilar for denosumab, and the FDA and EMA accepted its asthma biosimilar application for review.
Latest:
Resources for Patients and Providers on Adalimumab BiosimilarsExpert providers in inflammatory diseases provide additional resources on biosimilars and adalimumab biosimilar for patients and providers.
